Clinical trials: Rifampin
Brucellosis, Osteoarthritis
Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization(WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated antimicrobial…
- Trial name
- BRUCE (NCT07779629)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- China
- Sponsor
- The First Affiliated Hospital of Shihezi University
Healthy Volunteers
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
This is a 2-part study to evaluate the effect of multiple doses of rifampin or efavirenz on the PK, safety, and tolerability of single doses of fedratinib in healthy subjects.
- Trial name
- NCT03983239
- Testing
- Fedratinib, Rifampin, Efavirenz
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Sclerosis
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
This is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy…
- Trial name
- NCT06064539
- Testing
- Tolebrutinib, gemfibrozil, rifampicin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
This is a Phase 1, single center, fixed sequence, open label, drug-drug interaction study of the effect of multiple doses of rifampin 600 mg daily, a strong CYP3A inducer, on the exposure of mifepristone at 2 dose levels.
- Trial name
- NCT03258372
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Drug Interaction
The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects
This study is designed to estimate the drug interaction between RIF and ABT. This will be a single-center, open-label, parallel study in healthy adult subjects.
- Trial name
- NCT04006353
- Testing
- ABT, RIF
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Public Health Clinical Center
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
- Trial name
- NCT04553406
- Testing
- SPR720, Open-label Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Spero Therapeutics
Atherothrombotic Diseases
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
This study is to evaluate the effect of multiple doses of rifampin on the single-dose PK of BMS 986141 with parameters like Cmax, AUC(INF), AUC(0-T), AUC(0-144h)
- Trial name
- NCT02957448
- Testing
- BMS 986141, Rifampin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Tuberculosis, Human Immunodeficiency Virus
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Tuberculosis (TB) remains a major global public health problem, particularly in low- and middle-income countries (LMICs) in Africa, Asia, and Eastern Europe.
- Trial name
- OptiRiMoxTB (NCT05575518)
- Testing
- Optimised rifamycin
- Where
- Tanzania
- Volunteers
- 414 people
- Sponsor
- Stellah Mpagama
Clinical Pharmacology
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
This is a phase I, open-label, two-part, fixed-sequence drug interaction study conducted to evaluate the effects of concomitant use of the potent CYP3A4 inhibitor itraconazole or the CYP3A4 inducer rifampin on the…
- Trial name
- NCT07374224
- Testing
- Rocbrutinib tablets, Itraconazole capsules, Rifampicin capsules
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Tuberculosis Infection
Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis
Tuberculosis burden in Vietnam increasing with contribution from low detection rates and increased drug resistance. There is a need to identify MDR-TB (MultiDrug Resistant Tuberculosis) among both notified TB cases and their…
- Trial name
- SNAP (NCT02175849)
- Where
- Vietnam
- Volunteers
- 596 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Metastatic Melanoma, BRAF V600 Mutation Positive
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing…
- Trial name
- NCT02608034
- Testing
- Itraconazole, Rifampin, Vemurafenib
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 32 people
- Sponsor
- Genentech, Inc.
Healthy
Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect
The primary objective of this trial is to investigate the relative bioavailability of BI 685509 given alone under fasted conditions (Reference, R) compared to the intake after a high fat, high caloric breakfast (Test 1, T1), to…
- Trial name
- NCT03116893
- Testing
- BI 685509 After Standardised Breakfast, Itraconazole, Rifampin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Hypertonic Saline for MAC
The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
- Trial name
- NCT04921943
- Testing
- Hypertonic saline, Azithromycin, Ethambutol
- Where
- 3 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
HIV Infections, Tuberculosis
Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an increased risk of contracting malaria.
- Trial name
- NCT00620438
- Testing
- Lumefantrine-artemether and nevirapine, lumefantrine-artemether and efavirenz, Lumefantrine-artemether and rifampicin
- Where
- Uganda
- Volunteers
- 90 people
- Sponsor
- Makerere University
Tuberculosis, HIV Infections
Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
In this pilot study the pharmacokinetics and safety of the antiretroviral combination of co-formulated emtricitabine/tenofovir/efavirenz will be studied in HIV-positive patients with pulmonary tuberculosis (TB) who are…
- Trial name
- PETE (NCT00474435)
- Testing
- Emtricitabine/tenofovir/efavirenz
- Where
- Tanzania
- Volunteers
- 30 people
- Sponsor
- African Poverty Related Infection Oriented Research Initiative
Infective Endocarditis
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months…
- Trial name
- RIFREE (NCT07345325)
- Testing
- Rifampin-free regimen, Rifampin containing regimen
- Where
- 31 sites in France
- Volunteers
- 422 people
- Sponsor
- Nantes University Hospital
Meningitis, Tuberculous, Pharmacokinetics
Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study
Tuberculous meningitis (TBM) is the most lethal form of tuberculosis infection, and is diagnosed in approximately 5-10% of TB patients.
- Conditions
- Meningitis, Tuberculous, Pharmacokinetics, Pharmacodynamics, Tolerability
- Trial name
- NCT01158755
- Testing
- Moxifloxacin
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Padjadjaran
Tuberculosis
Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa
The purpose of this study is to compare three strategies for finding TB cases in a rural Sub-Saharan African setting: 1) Screening all attendees of primary care clinics for TB; 2) Conducting household contact investigations of…
- Trial name
- Kharitode TB (NCT02808507)
- Testing
- Active TB case finding
- Where
- 2 sites in South Africa
- Volunteers
- 4,852 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Healthy
Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown product) in the blood when taken alone and in combination with either rifampin or…
- Trial name
- NCT01637636
- Testing
- tasimelteon, Rifampin, Ketoconazole
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals